Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer - PubMed (original) (raw)
doi: 10.1016/j.clbc.2012.07.001.
Edoardo Botteri, Maria Teresa Sandri, Angela Esposito, Laura Adamoli, Laura Zorzino, Angela Sciandivasci, Maria Cristina Cassatella, Nicole Rotmensz, Gaetano Aurilio, Giuseppe Curigliano, Aron Goldhirsch, Franco Nolè
Affiliations
- PMID: 23040002
- DOI: 10.1016/j.clbc.2012.07.001
Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer
Elisabetta Munzone et al. Clin Breast Cancer. 2012 Oct.
Abstract
Background: Breast cancer is a heterogeneous disease. Circulating tumor cell (CTC) enumeration might be useful to identify different risk categories within each molecular subtype.
Methods: We retrospectively analyzed 203 consecutive patients with metastatic breast cancer with baseline CTC enumeration performed with CellSearch (Veridex Corp, Warren, NJ) between March 2005 and July 2011. Patients were categorized into 3 prognostic groups based on the number of CTCs (0, 1-4, and ≥ 5) and into 5 categories based on tumor biological characteristics: luminal-A (estrogen receptor [ER] and progesterone receptor [PR] > 1%, grade 1/2, human epidermal growth factor 2 [HER2]-negative [HER2(-)], Ki67 value < 14%); luminal-B (ER and/or PR > 1%, grade 3, HER2(-), Ki67 value > 14%); luminal-B HER2-positive [HER2(+)] (ER and/or PR > 1%, any grade, HER2(+), Ki-67 value any); HER2(+) (HER2 overexpressed/fluorescence in situ hybridization [FISH] amplified, ER and PR absent); triple negative (TN) (ER and PR 0%, HER2 not overexpressed/FISH not amplified).
Results: Median age was 57 years (range 31-78 years). Twenty-seven patients (13.3%) had luminal-A category, 105 (51.7%) patients had luminal-B, 29 (14.3%) patients had luminal-B HER2(+), 24 patients (11.8%) had HER2(+), and 18 patients (8.9%) had TN. CTCs were mostly found in patients with luminal-A/luminal-B HER2(-) subtype. At multivariable analysis, CTC count was a significant predictive factor for overall survival (OS) in all molecular subtypes (log-rank P < .01). Patients with 0 CTCs/7.5 mL blood and all subtypes, except HER2(+), seem to perform better compared with other categories.
Conclusion: These findings confirm CTCs as an important prognostic factor for metastatic breast cancer in all molecular subtypes. Larger studies could help identify metastatic breast cancer subgroups in which CTC analysis would be particularly useful.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
- Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Giordano A, et al. Breast Cancer Res Treat. 2011 Sep;129(2):451-8. doi: 10.1007/s10549-011-1645-5. Epub 2011 Jun 28. Breast Cancer Res Treat. 2011. PMID: 21710134 - Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW. Park S, et al. Breast. 2012 Feb;21(1):50-7. doi: 10.1016/j.breast.2011.07.008. Epub 2011 Aug 23. Breast. 2012. PMID: 21865043 - [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM, Zhang BN, Xuan LX, Zhao P. Zhang HM, et al. Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19950556 Chinese. - Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.
Cadoo KA, Fornier MN, Morris PG. Cadoo KA, et al. Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21. Q J Nucl Med Mol Imaging. 2013. PMID: 24322788 Review. - Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Onstenk W, et al. Cancer Treat Rev. 2013 Nov;39(7):691-700. doi: 10.1016/j.ctrv.2013.04.001. Epub 2013 May 16. Cancer Treat Rev. 2013. PMID: 23683721 Review.
Cited by
- Personalized treatment approach for HER2-positive metastatic breast cancer.
Pandey P, Chaudhary R, Tripathi D, Lavudi K, Dua K, Weinfeld M, Lavasanifar A, Rajinikanth PS. Pandey P, et al. Med Oncol. 2024 Sep 25;41(11):252. doi: 10.1007/s12032-024-02504-4. Med Oncol. 2024. PMID: 39320608 Review. - PIK3CA mutation analysis in circulating tumor cells of patients with hormone receptor positive metastatic breast cancer.
Marino E, Mauro C, Belloni E, Picozzi M, Favalli V, Cassatella MC, Zorzino L, Giacò L, Pelicci PG, Barberis M, Sandri MT, Bernard L. Marino E, et al. Biochem Biophys Rep. 2024 Aug 26;39:101805. doi: 10.1016/j.bbrep.2024.101805. eCollection 2024 Sep. Biochem Biophys Rep. 2024. PMID: 39282094 Free PMC article. - Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
Peng X, Gong C, Zhang W, Zhou A. Peng X, et al. Front Oncol. 2023 Jan 16;12:1091088. doi: 10.3389/fonc.2022.1091088. eCollection 2022. Front Oncol. 2023. PMID: 36727075 Free PMC article. Review. - Oral Contraceptive Use and Assessment of Breast Cancer Risk among Premenopausal Women via Molecular Characteristics: Systematic Review with Meta-Analysis.
Barańska A. Barańska A. Int J Environ Res Public Health. 2022 Nov 21;19(22):15363. doi: 10.3390/ijerph192215363. Int J Environ Res Public Health. 2022. PMID: 36430082 Free PMC article. - Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile.
Zhu C, Xu J, Sun J, Cui S, Sun Y, Yu T, Wang C, Wang T, Wu Y, Ju F, Yao J, Liu K, Zhang W, Guan X. Zhu C, et al. J Clin Med. 2022 Oct 14;11(20):6067. doi: 10.3390/jcm11206067. J Clin Med. 2022. PMID: 36294386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous